Vertaling van "psychiatric disorders including alcoholism and drug " (Frans → Nederlands) :

En 1974, le concept du « médecin malade » est apparu dans un document de l’Association Médicale Américaine (American Medical Association ou AMA) intitulé « The Sick Physician : impairment by psychiatric disorders including alcoholism and drug dependencies » 83 .
In 1974 dook het begrip ‘zieke arts’ op in een document van de Amerikaanse Medische Vereniging (American Medical Association of AMA) met als titel ‘The Sick Physician: impairment by psychiatric disorders including alcoholism and drug dependencies’ 83 .

« [an impaired physician] is one unable to fulfill professional or personal responsibilities because of psychiatric illness, alcoholism, or drug dependency» (un médecin en incapacité est celui qui est incapable de remplir ses obligations professionnelles ou personnelles en raison d’une maladie psychiatrique, de l’alcoolisme ou de la dépendance à une drogue) 83
‘[an impaired physician] is one unable to fulfill professional or personal responsibilities because of psychiatric illness, alcoholism, or drug dependency’ (een arbeidsongeschikte arts is een arts die niet in staat is om zijn professionele of persoonlijke verplichtingen na te komen vanwege een psychiatrische aandoening, alcoholisme of drugsverslaving) 83

folding and its platform for drug and target discovery, the company is building a pipeline, initially for neurodegenerative and respiratory conditions. FoldRx’s pipeline includes a program in advanced clinical development to treat genetic neurologic and cardiovascular disorders, Transthyretin (TTR) Amyloid Polyneuropathy (ATTR-PN) and TTR Amyloid Cardiomyopathy (ATTR-CM), and a discovery program in cystic fibrosis, Parkinson’s, and Huntington’s disease based on its broad, proprietary, yeast-based drug discovery platform.
FoldRx is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis) based on the pioneer work of its scientific founders, Jeffery Kelly (The Scripps Research Institute) and Susan Lindquist (Whitehead Institute).